Medicinal plants used in the treatment of tuberculosis - Ethnobotanical and ethnopharmacological approaches.
Antimycobacterial agents
Evidence-based medicine
Herbal medicine
Multi drug-resistance
Mycobacterium
Traditional healing systems
Journal
Biotechnology advances
ISSN: 1873-1899
Titre abrégé: Biotechnol Adv
Pays: England
ID NLM: 8403708
Informations de publication
Date de publication:
15 11 2020
15 11 2020
Historique:
received:
29
12
2016
revised:
22
06
2017
accepted:
05
07
2017
pubmed:
9
9
2020
medline:
13
1
2021
entrez:
8
9
2020
Statut:
ppublish
Résumé
Tuberculosis is a highly infectious disease declared a global health emergency by the World Health Organization, with approximately one third of the world's population being latently infected with Mycobacterium tuberculosis. Tuberculosis treatment consists in an intensive phase and a continuation phase. Unfortunately, the appearance of multi drug-resistant tuberculosis, mainly due to low adherence to prescribed therapies or inefficient healthcare structures, requires at least 20 months of treatment with second-line, more toxic and less efficient drugs, i.e., capreomycin, kanamycin, amikacin and fluoroquinolones. Therefore, there exists an urgent need for discovery and development of new drugs to reduce the global burden of this disease, including the multi-drug-resistant tuberculosis. To this end, many plant species, as well as marine organisms and fungi have been and continue to be used in various traditional healing systems around the world to treat tuberculosis, thus representing a nearly unlimited source of active ingredients. Besides their antimycobacterial activity, natural products can be useful in adjuvant therapy to improve the efficacy of conventional antimycobacterial therapies, to decrease their adverse effects and to reverse mycobacterial multi-drug resistance due to the genetic plasticity and environmental adaptability of Mycobacterium. However, even if some natural products have still been investigated in preclinical and clinical studies, the validation of their efficacy and safety as antituberculosis agents is far from being reached, and, therefore, according to an evidence-based approach, more high-level randomized clinical trials are urgently needed.
Identifiants
pubmed: 32896577
pii: S0734-9750(20)30131-2
doi: 10.1016/j.biotechadv.2020.107629
pii:
doi:
Substances chimiques
Anti-Infective Agents
0
Antitubercular Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
107629Informations de copyright
Copyright © 2020. Published by Elsevier Inc.